Kidney-resident macrophages — a role for healing during acute kidney injury?
These kidney macrophages reprogram to a developmental state after kidney injury, similar to those in newborn mice.
These kidney macrophages reprogram to a developmental state after kidney injury, similar to those in newborn mice.
The IASLC WCLC meeting, held in Barcelona this year, covered many interesting topics and reported data from clinical trials relevant to the management of lung cancer. In the… read more.
Most patients die within 5 years and spend two-thirds of remaining life as an inpatient.
In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients, the panel staked out their positions at the International… read more.
Professor Sagar Lonial (Atlanta, USA) and Professor Philippe Moreau (Nantes, France) discuss whether patients are being cured now and what the future holds.
Article written by Tom Collins. Interview by Esther Drain.
Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing that could provide even more options, said Professor Philippe Moreau, head of the haematology department at University Hospital in Nantes, France.
Article written by Tom Collins. Interview by Esther Drain. Meletios Dimopoulos, MD, professor and chairman of clinical therapeutics at the University of Athens and a long-time expert in… read more.
Article written by Tom Collins. Interview by Esther Drain In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients,… read more.
Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing… read more.
Professor Philippe Moreau (Nantes, France) and Professor Paul Richardson (Boston, USA) give their opinion on sequencing in myeloma and options at relapse and Dr Rakesh Popat (London, UK)… read more.
In the ‘Great Debates in MM’ session Professor Paul Richardson (Boston, USA) argued the pros and cons of RVd vs KRd in the frontline. Written by Esther Drain
Many newly diagnosed patients receive multiple myeloma treatment for more than 12 months, according to data collected from treatment centers around the world, showing that the shift away… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.